Pre-made Melrilimab biosimilar ( Whole mAb, anti-IL1RL1 therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-340
Anti-IL1RL1 therapeutic antibody (Pre-made Melrilimab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Melrilimab (formerly GSK 3772847) was a monoclonal antibody targeting interleukin-1 receptor-like 1 (IL1RL1 or ST2 or IL-33R), which was being developed by GlaxoSmithKline for the treatment of asthma and atopic dermatitis. Clinical development was ongoing in the US and the UK.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-IL1RL1 therapeutic antibody (Pre-made Melrilimab biosimilar,Whole mAb)|
|Highest_Clin_Trial (Jan '20)||Phase-II|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Conditions Discontinued||Asthma;Atopic dermatitis|